It is made available under a CC-BY-NC 4.0 International license .

- 1 Title: Long-term Outcomes of Poor-grade Aneurysmal Subarachnoid Haemorrhage: A Multicentre
- 2 Observational Cohort Study
- 3 Authors:
- 4 Bangyue Wang<sup>1,2</sup><sup>+</sup>,MD, Tianxing Li<sup>1</sup><sup>+</sup>,MD, Yan Zhao<sup>1</sup><sup>+</sup>,MD, Tian Zhou<sup>3</sup>,MD, Ruyi Wang<sup>4</sup>,MD, Yang
- 5 Li<sup>1</sup>,MD, Xiuhu An<sup>1</sup>,MD, Jiheng Hao<sup>5\*</sup>,MD, Kaijie Wang<sup>6\*</sup>,MD, and Xinyu Yang<sup>1\*</sup>,PhD
- 6 **†**Bangyue Wang, Tianxing Li, and Yan Zhao contributed equally and are co-first authors.
- 7 \*Correspondence:
- 8 Jiheng Hao, Email: haojiheng@163.com
- 9 Kaijie Wang, Email: lwapple168168@sina.cn
- 10 Xinyu Yang, Email: yangxinyu@tmu.edu.cn. Tianjin Medical University General Hospital, No. 154
- 11 An-Shan Road, Tianjin 300052, China
- 12 1 Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300070, China.
- 13 2 Department of Neurosurgery, The Second Affiliated Hospital of Anhui Medical University, Hefei,
- 14 230601, China.
- 15 3 Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine,
- 16 Jinhua, 321000, Zhejiang, China.
- 17 4 Department of Emergency Surgery, The First Affiliated Hospital of Bengbu Medical University,
- 18 Bengbu, 233030, Anhui, China.
- 19 5 Department of Neurosurgery, Liaocheng People's hospital, Liaocheng, 252000, Shandong, China.
- 20 6 Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, 063000, Hebei, China.
- 21

It is made available under a CC-BY-NC 4.0 International license .

### 22 Abstract:

#### 23 BACKGROUND:

24 Despite advancements in neurosurgery and intensive care that reduce overall mortality, 25 poor-grade aneurysmal subarachnoid haemorrhage (aSAH) (World Federation of Neurosurgical 26 Societies [WFNS] grades IV and V) remains a significant clinical challenge and is associated with 27 persistently high mortality rates. The aim of this study was to assess the long-term outcomes of 28 poor-grade aSAH and to identify factors influencing patient prognosis to guide clinical management. 29 **METHODS:** 30 A multicentre, observational cohort study was conducted across 12 regional centres in northern 31 China. The study included patients with poor-grade aSAH admitted from 2017 to 2020. The baseline 32 data included demographics, clinical presentation, aneurysm characteristics, and treatment modalities. 33 Outcome data, including survival status, mortality along with its associated causes and timing, and 34 modified Rankin scale (mRS) scores, were collected prospectively at the last medical follow-up. 35 Changes in case fatality over time were quantified with weighted linear regression. Survival analysis 36 was performed to estimate survival and hazard ratios for death. Binary logistic regression was 37 performed to estimate the odds ratio for dependency (mRS=3-5).

#### 38 **RESULTS:**

Among the 1,589 enrolled patients, 1,339 were successfully followed, with an average follow-up of 26.37 months. Among them, 61.5% (824/1,339) were dependent or died. The overall mortality rate was 51% (684/1,339), and 21.3% (140/655) of the survivors were dependent. The risk factors for mortality included age  $\geq 65$  years, previous history of stroke, and WFNS grade V. Additionally,

It is made available under a CC-BY-NC 4.0 International license .

conservative treatment and endovascular treatment were identified as risk factors and protective

44	factors, respectively, compared with surgical treatment. WFNS grade V and middle cerebral artery
45	aneurysms are independent risk factors for dependency.
46	CONCLUSIONS:
47	Although there has been a downward trend in recent years, the long-term mortality rate for
48	poor-grade aSAH has remained significantly high at 51%, with 21.3% of survivors being dependent.
49	Active aneurysm treatment, to the extent possible, is crucial for improving the prognosis of these
50	patients.
51	KEYWORDS: aneurysm; subarachnoid haemorrhage; outcome; poor-grade aSAH; survival analysis
52	

It is made available under a CC-BY-NC 4.0 International license .

## 53 INTRODUCTION

54 The mortality and disability rates associated with aneurysmal subarachnoid haemorrhage (aSAH) are exceedingly high, with the mortality rate reaching approximately 35%<sup>1</sup>. However, with the 55 56 progress in modern neurosurgical techniques and the proliferation of neurointensive care units, there has been a significant reduction in the overall mortality rate of aSAH<sup>2-6</sup>. Despite this encouraging 57 58 trend, the mortality rate for poor-grade (World Federation of Neurosurgical Societies [WFNS] grade IV and V) aSAH patients remains high. Although poor-grade aSAH accounts for only approximately 59 18–30% of all aSAH cases<sup>7-9</sup>, it contributes to more than half of aSAH-related deaths<sup>10-12</sup>, and the 60 61 management of these patients remains a clinical challenge. Previous studies have demonstrated that 62 more than 60% of these patients die or are left with disabilities<sup>9, 13, 14</sup>, imposing a significant burden on society and families<sup>15, 16</sup>. Therefore, describing the long-term prognosis of poor-grade cases and 63 64 analysing their influencing factors are crucial for guiding the management of patients with poor-grade aSAH in clinical practice and preventing the occurrence of adverse events in the long term. To the best 65 66 of our knowledge, current reports on the long-term prognosis of poor-grade aSAH are mostly based on small sample sizes and are single-centre retrospective studies<sup>17</sup>, which are not able to fully reflect the 67 68 epidemiological characteristics and long-term prognosis of the poor-grade aSAH population. In this 69 study, we used the Chinese Multicentre Cerebral Aneurysm Database to analyse long-term outcomes 70 and additional survival data of poor-grade aSAH patients to provide clinical evidence that could help 71 enhance the understanding of patient prognosis and assist in providing informed and reasonable 72 management for this challenging subgroup.

73 **METHODS** 

It is made available under a CC-BY-NC 4.0 International license .

### 74 **Patients**

75	This prospective, multicentre, observational cohort study (chictr.org.cn, ID: ChiCTR2200065083)
76	was approved by the Ethics Committee (the Ethics Committee of Tianjin Medical University General
77	Hospital (IRB2021-YX-178-01)) and was performed in accordance with the Declaration of Helsinki.
78	The requirement for informed consent was waived by the ethics committee because of the
79	observational design of this study.
80	This study utilised the Chinese Multicentre Cerebral Aneurysm Database, which consecutively
81	enrolled patients from 12 regional centres across 4 provinces in northern China. Data from all patients
82	with aneurysmal subarachnoid haemorrhage (SAH) admitted from 2017 to 2020 were entered into the
83	Chinese Multicentre Aneurysm Database (CMAD).
84	The inclusion criteria for the present study were all consecutive adult patients (≥18 years)
85	admitted to the neuro-intensive care unit (ICU) or neurosurgical department because of the first
86	diagnosis of poor-grade SAH, defined as WFNS grades IV and V with an aneurysmal cause. The
87	noninclusion criteria were aSAH rehospitalization, poor echogenicity or inability to obtain inpatient
88	medical records, baseline characteristics or telephone number. Among the 5837 aSAH patients in the
89	database, 1589 eligible patients admitted with WFNS grades IV and V were identified.
90	Study design and data collection
91	For eligible patients included in the study, baseline demographic data, WFNS grade, and Fisher
92	grading scale score were directly obtained by neurosurgeons at each centre upon admission and
93	recorded from admission to discharge. In addition, the size of the aneurysm, aneurysm multiplicity,

94 aneurysm location, and aneurysm treatment methods were recorded. The diagnosis of SAH was

It is made available under a CC-BY-NC 4.0 International license .

95	confirmed by head computed tomography (CT) or lumbar puncture. Evidence of aneurysms was
96	verified by neuroradiologists through computed tomography angiography (CTA), digital subtraction
97	angiography (DSA), or magnetic resonance angiography (MRA). The clinical management of patients
98	and the indications for different aneurysm treatment strategies were determined by an interdisciplinary
99	neurovascular team on the basis of aneurysm treatment guidelines after discussion with family
100	members. The final treatment methods included surgical treatment, endovascular treatment, or
101	conservative treatment. Conservative treatment was defined as not performing surgical repair for
102	ruptured aneurysms. In addition to medication, these patients may have undergone simple external
103	drainage surgery, simple haematoma removal, or decompressive craniectomy, which are interventions
104	taken for patients with gradually declining consciousness due to hydrocephalus or intracerebral
105	haemorrhage (ICH).
106	Outcome measures
107	Survival analysis data were collected starting on the day of ictus. The follow-up evaluation was
108	accomplished primarily via standardized telephone surveys with the patients or close relatives. The
100	

110 survival and mortality status at discharge and at the time of follow-up, as well as the modified Rankin

final follow-up period was from June 1, 2023, to June 1, 2024. The outcome measures included

109

111 scale (mRS) score. Additionally, the primary outcome was death, and the secondary outcome was

112 dependent living status (dependency), defined as an mRS score of 3–5 (indicating an inability to walk

- 113 unassisted) at the time of follow-up. The patient characteristics analysed included sex, age, living area
- 114 (rural/urban), hypertension, diabetes, hyperlipidaemia, smoking, alcohol consumption, previous
- 115 history of stroke, aneurysm multiplicity, aneurysm location, WFNS grade, Fisher grading scale on

It is made available under a CC-BY-NC 4.0 International license .

116	admission, presence of ICH or intraventricular haemorrhage (IVH) on admission, aneurysm size,
117	admission delay, intervention delay (surgical and endovascular treatment), length of hospital stay,
118	cause of death, and general information on treatment (surgical, endovascular, or conservative
119	treatment; use of lumbar puncture or external ventricular drainage). The causes of death are classified
120	as follows: (1) direct effect of the primary haemorrhage, (2) aneurysm rebleeding, (3) refractory
121	cerebral oedema leading to brainstem herniation, (4) withdrawal of life-sustaining treatment for
122	patients in a persistent vegetative state, (5) infection, (6) multiple organ dysfunction syndrome
123	(MODS), (7) hydrocephalus, (8) cardiac disease, (9) other cerebrovascular disease (e.g., intracerebral
124	haemorrhage, cerebral infarction), (10) cancer, (11) pulmonary embolism, (12) accidents (e.g., car
125	accidents), and (13) unknown.
126	Statistical methods

127 Continuous data are described using the mean (SD) or median (interquartile range), depending on their distribution. Categorical data are described as counts (percentages). Multiple imputation methods 128 129 are used to address missing data issues. The fully conditional specification method is employed to 130 estimate missing values of covariates via iterative Markov chain Monte Carlo methods. Kaplan-Meier 131 curves were plotted for survival analysis of different groups and the overall population. Cox 132 proportional hazard regression models were used to estimate the hazard ratio (HR) of death after 133 poor-grade aSAH. Binary logistic regression models were used to identify factors impacting 134 dependent living (defined as mRS 3-5) after poor-grade aSAH. The variables for multivariate analysis 135 included sex, age, and variables with p < 0.2 in the univariate analysis. The p value and 95% 136 confidence interval (CI) were calculated. On this basis, the cumulative mortality rates at various time

137	points for the overall risk factor and each risk factor are summarized. Linear regression, weighted by
138	the inverse of the standard error of the case fatality rate for each study, was used to quantify the
139	relationship between the case fatality rate and the mid-central year of the study. Continuous variables
140	were tested via t tests or Wilcoxon tests as appropriate. Pearson's chi-square analysis was used to test
141	for differences in the stratified distributions of various factors. All analyses were conducted via SPSS
142	version 27.0 (SPSS Inc., Chicago, IL) or R version 4.0.3(https://www.R-project.org/).
143	RESULTS
144	Baseline characteristics
145	From 2017–2020, a total of 9,826 eligible intracranial aneurysm patients were included, 5,837 of
146	whom with subarachnoid haemorrhage (SAH) met the criteria, and a total of 1,589 eligible
147	consecutive poor-grade aSAH patients were included (Figure S1). In our study, they accounted for
148	27.2% of the overall SAH cases. Among the 1,589 poor-grade aSAH patients included in this study,
149	the average age (SD) of the patients was 62.31 years (11.57), with 67.7% being female. There were
150	1,005 WFNS Grade IV patients and 584 WFNS Grade V patients. The location of the aneurysm was
151	missing for 12 (0.08%) patients, with the most common location being the internal carotid artery (ICA,
152	39.5%). Data on the maximum diameter of the aneurysm were missing for 269 (20%) patients, with
153	the most common size being 4-6.9 mm, totalling 344 (35.5%) patients. The treatments included
154	surgical, endovascular, and conservative treatment, with 670 (42.1%) patients receiving surgical
155	treatment, 539 (49.2%) patients receiving endovascular treatment, and 380 (23.9%) patients receiving
156	conservative treatment (Table 1).
157	Table 1 Baseline characteristics table of 1,589 poor-grade subarachnoid haemorrhage patients grouped

It is made available under a CC-BY-NC 4.0 International license .

Variable	Missing, n(%)	WFNS IV grade(n=1005)	WFNS V grade(n=584)	Overall(n=1589)
Age, years , mean±SD, median(IQR)	0(0%)	62.18±11.67,64(54;70)	62.55±12.41,63(55;70)	62.31±11.57, 64(55;70)
Female, n(%)	0(0%)	712(70.8%)	365(62.5%)	1077(67.7%)
Living area, n(%)	0(0%)	(·····)		
Urban	0(0%)	289(28.7%)	182(31.1%)	471(29.6%)
Rural	0(0%)	716(71.2%)	402(68.8%)	1118(70.3%)
Medical history				
Hypertension, n(%)	0(0%)	638(63.4%)	398(68.1%)	1036(65.1%)
Diabetes, n(%)	0(0%)	83(8.2%)	34(5.8%)	117(7.3%)
Hyperlipidemia, n(%)	0(0%)	19(1.8%)	5(0.8%)	24(1.5%)
Previous stroke history, n(%)	0(0%)	129(12.8%)	89(15.2%)	218(13.7%)
Behavioural history	1			1
Drinking, n(%)	0(0%)	85(8.4%)	49(8.3%)	134(8.4%)
Smoking, n(%)	0(0%)	116(11.5%)	70(11.9%)	186(11.7%)
Aneurysm characteristics				
Multiple, n(%)	0(0%)	196(19.5%)	102(17.4%)	298(18.7%)
Location of the largest aneurysm, n(%)	12(0.08%)			
ICA		427(42.4%)	202(34.5%)	629(39.5%)
MCA		169(16.8%)	135(23.1%)	304(18.1%)
ACA		286(28.4%)	159(27.2%)	445(28.0%)
PCircA		112(11.1%)	77(13.1%)	189(11.8%)
Size of the largest aneurysm, n(%)	269(20%)			
<4.0 mm		207(25%)	96(17%)	303(22.6%)
4.0-6.9 mm		309(37.3%)	167(32.6%)	476(35.5%)
7-9.9 mm		114(13.7%)	78(15.2%)	192(14.3%)
≥10mm		48(5.7%)	51(9.9%)	99(7.3%)
Clinical assessment	·			
Fisher scale	0(0%)			
II		405(40.2%)	122(20.8%)	527(33.1%)
III		291(28.9%)	123(21%)	414(26.0%)
IV		305(30.7%)	339(58.0%)	648(40.7%)
Presence with ICH/IVH, n(%)	0(0%)	305(30.7%)	339(58.0%)	648(40.7%)
Treatment	0(%)			
Endovascular		495(49.2%)	51(28.9%)	539(33.9%)

158 by WFNS grade at admission

It is made available under a CC-BY-NC 4.0 International license .

treatment, n(%)				
· · ·				
Surgical treatment,		323(32.1%)	61(24.1%)	670(42.1%)
n(%)		,	× ,	, , , , , , , , , , , , , , , , , , ,
Conservative		187(18.6%)	99(46.9%)	380(23.9%)
treatment, n(%)		187(18.0%)	<i>99</i> (40. <i>97</i> 0)	380(23.970)
External ventricular		100(10.00()	20(100()	220/14 40/2
drainage, n(%)		109(10.8%)	38(18%)	230(14.4%)
Lumbar cistern drainage,			20/10 10/	
n(%)		273(27.2%)	39(18.4%)	391(24.6%)
Intervention delay				
(endovascular and	0.(00.()			10 (0.0 ( 0.7)
surgical treatment), h,	0(0%)	15(4;31)	6(3;20)	12(3;26.25)
median(IQR)				
Admission delay, h,	0.000.00			
median(IQR)	0(0%)	5(3;13)	4(3;8)	5(3;10)
Length of stay, d,				
median(IQR)	0(0%)	16(8;24.5)	10(2;24)	15(5;24)
mRS at discharge	0(0%)		I	I
0-2		519(51.6%)	23(10.9%)	597(39.7%)
3-5		486(48.4%)	188(89%)	847(60.2%)
In-hospital deaths, n(%)	0(0%)	50(4.9%)	49(23.2%)	145(9.2%)


159 ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCircA,

160 posterior circulatory artery

161 Survival analysis

It is made available under a CC-BY-NC 4.0 International license .

162	In this study, we used the Kaplan-Meier method to generate time-survival-related survival
163	curves on the basis of associated factors, as shown in Figure 1. A total of 1,339 out of 1,589 patients
164	were included in the survival analysis, accounting for 2,942.83 follow-up years, with an average
165	follow-up of 26.37 months (range, 0.5-88 months). During the follow-up, a total of 61.5% (824 out of



166 1,339) of the patients either died or survived with dependency status.

167 **Figure. 1** Probability of survival by risk factors.(a), Kaplan-Meier curves of the complete cohort, (b-f)

168 stratified by sex (b),age (c),WFNS grade (d),treatment (e) and previous history of stroke (f).

It is made available under a CC-BY-NC 4.0 International license .

169	There were 684 (51%) patients with poor-grade aSAH who died from all causes, while 655 (49%)
170	patients were still alive at the time of follow-up. Figure S2 illustrates the distribution of causes of
171	death, whereas Table S1 elaborates on their temporal distribution. The survival rates at various time
172	points related to various influencing factors are shown in Table 2. Of these rates, 145 patients died in

the hospital.

174 **Table 2** Cumulative 3-year survival probability rate (95% CI) according to different associated factors

	1mo(95%CI)	3mo(95%CI)	6mo(95%CI)	1y(95%CI)	2y(95%CI)	3y(95%CI)
All	60.3%	59.1%	58.0%	56.5	54.1%	51.1%
All	(57.8%-63.0%)	(56.5%-61.8%)	(55.4%-60.7%)	(53.9%-59.2%)	54.1% $51.1%$ $6)$ $(51.5%-56.8%)$ $(48.5%-53.9%)$ $46.1%$ $42.7%$ $6)$ $(42.9%-49.6%)$ $(39.5%-46.2%)$ $55.6%$ $53.3%$ $6)$ $(52.5%-59.0%)$ $(50.2%-56.7%)$ $49.0%$ $47.1%$ $6)$ $(46.3%-53.0%)$ $(43.9%-50.5%)$ $33.8%$ $30.6%$ $6)$ $(27.6%-41.4%)$ $(24.5%-38.1%)$ $48.10%$ $45.10%$ $6)$ $(44.1%-52.5%)$ $(41.1%-49.6%)$ $36.8%$ $34.6%$ $6)$ $(32.8%-41.2%)$ $(30.7%-39.1%)$ $47.6%$ $44.6%$ $6)$ $(43.2%-62.3%)$ $(41.0%-60.3%)$ $51.9%$ $49.7%$ $6)$ $(62.5%-71.2%)$ $(56.6%-65.8%)$ $6)$ $(66.0%-73.7%)$ $(64.2%-72.0%)$ $11.3%$ $9.7%$	
Age≥60	53.6%	51.8%	50.8%	48.9%	46.1%	42.7%
Age_00	(50.3%-57.0%)	(48.6%-55.3%)	9.1%         58.0%           56.5%-61.8%)         (55.4%-60.7%)           11.8%         50.8%           48.6%-55.3%)         (47.5%-54.2%)           i0.2%         59.4%           57.1%-63.5%)         (56.2%-62.7%)           i4.8%         53.7%           51.6%-58.2%)         (50.5%-57.1%)           i1.6%         40.5%           35.0%-49.3%)         (34.0%-48.2%)           33.0%         51.80%           49.3%-57.6%)         (47.8%-56.2%)           i.1.5%         40.1%           37.4%-46.0%)         (36.1%-44.6%)           2.7%         52.3%           46.5%-59.7%)         (46.1%-59.3%)           i7.5%         57.5%           48.9%-67.8%)         (48.9%-67.8%)           i2.5%         71.0%           68.5%-76.8%)         (66.9%-75.3%)           i5.5%         74.1%           72.0%-79.2%)         (70.5%-77.8%)           3.7%         13.7%	(45.6%-52.4%)	(42.9%-49.6%)	(39.5%-46.2%)
Female	61.7%	60.2%	59.4%	57.8%	55.6%	53.3%
remaie	(58.6%-65.0%)	(57.1%-63.5%)	(56.2%-62.7%)	(54.7%-61.1%)	(52.5%-59.0%)	(50.2%-56.7%)
Uupartancian	56.1%	54.8%	53.7%	51.9%	49.0%	47.1%
Hypertension	(52.9%-59.5%)	(51.6%-58.2%)	(50.5%-57.1%)	(48.7%-55.3%)	(46.3%-53.0%)	(43.9%-50.5%)
Previous history of	44.9%	41.6%	40.5%	37.8%	33.8%	30.6%
stroke	(38.2%-52.6%)	(35.0%-49.3%)	(34.0%-48.2%)	(31.4%-45.4%)	(27.6%-41.4%)	(24.5%-38.1%)
Presence of	54.6%	53.30%	51.80%	50.50%	48.10%	45.10%
ICH/IVH	(50.5%-58.9%)	(49.3%-57.6%)	(47.8%-56.2%)	(46.5%-54.9%)	(44.1%-52.5%)	(41.1%-49.6%)
WFNS V grade	42.5%	41.5%	40.1%	38.7%	36.8%	34.6%
wring v grade	(38.4%-47.0%)	(37.4%-46.0%)	(36.1%-44.6%)	(34.7%-43.2%)	(32.8%-41.2%)	(30.7%-39.1%)
7-9.9 mm	53.6%	52.7%	52.3%	50.0%	47.6%	44.6%
7-9.9 mm	(47.4%-60.6%)	(46.5%-59.7%)	(46.1%-59.3%)	(43.8%-57.0%)	(41.4%-54.7%)	(38.4%-51.9%)
>10,	59.4%	57.5%	57.5%	55.7%	51.9%	49.7%
≥10mm	(50.8%-69.6%)	(48.9%-67.8%)	(48.9%-67.8%)	(47.0%-66.0%)	(43.2%-62.3%)	(41.0%-60.3%)
Complete 1 to a to a set	73.9%	72.5%	71.0%	69.%	66.70%	61.0%
Surgical treatment	(69.9%-78.1%)	(68.5%-76.8%)	(66.9%-75.3%)	(65.5%-74.0%)	(62.5%-71.2%)	(56.6%-65.8%)
Endovascular	76.3%	75.5%	74.1%	72.3%	69.7%	68.0%
treatment	(72.8%-79.9%)	(72.0%-79.2%)	(70.5%-77.8%)	(68.0%-76.1%)	(66.0%-73.7%)	(64.2%-72.0%)
Conservative	15.8%	13.7%	13.7%	12.8%	11.3%	9.7%
treatment	(12.4%-20.3%)	(10.5%-18.0%)	(10.5%-18.0%)	(9.7%-17.0%)	(8.4%-15.3%)	(7.0%-13.6%)

175

In the Cox regression analysis, age ≥65 years (HR (95% CI): 1.677 (1.423-1.976), p<0.001),

It is made available under a CC-BY-NC 4.0 International license .

176 previous history of stroke (HR (95% CI): 1.280 (1.051-1.557), p=0.014), WFNS grade V (HR (95%

177 CI): 1.566 (1.330-1.845), p<0.001), and conservative treatment (HR (95% CI): 2.580 (2.123-3.136),

178 p<0.001) were identified as risk factors for death in poor-grade aSAH patients, whereas being female

179 (HR (95% CI): 0.822 (0.700-0.966), p=0.017) and the use of endovascular treatment compared with

180 surgical treatment (HR (95% CI): 0.810 (0.661-0.994), p=0.044) were protective factors (Table 3).

181 **Table 3** Univariate and multivariable cox proportional hazards analysis of factors associated with 182 primary outcome

Marial 1	Univariat	Univariate analysis		ate analysis
Variable	<i>P</i> -value	HR (95% CI)	<i>P</i> -value	HR (95% CI)
Age≥65	< 0.001	1.982(1.699-2.312)	< 0.001	1.677(1.423-1.976)
Female	0.135	0.887(0.759-1.038)	0.017	0.822(0.700-0.966)
Living area (reference to rural)	0.530	0.949(0.806-1.117)		
Hypertension	< 0.001	1.411(1.195-1.666)	0.052	1.184(0.999-1.402)
Diabetes	0.342	1.143(0.868-1.506)		
Previous stroke history	< 0.001	1.635(1.349-1.983)	0.014	1.280(1.051-1.557)
Current alcohol use	0.427	0.894(0.677-1.180)		
Current smoker	0.899	1.015(0.805-1.280)		
Presence of ICH/IVH	< 0.001	1.294(1.113-1.504)	0.349	1.079(0.920-1.265)
WFNS V grade (reference to IV grade)	< 0.001	1.930(1.659-2.244)	< 0.001	1.566(1.330-1.845)
Multiple	0.386	1.087(0.900-1.313)		
Location of the largest aneurysm (reference				
to ICA)				
MCA	0.892	1.015(0.824-1.249)		
ACA	0.513	0.940(0.780-1.132)		
PirCA	0.211	1.162(0.918-1.470)		
Size of the largest aneurysm (reference				
to<4 mm)				
4.0-6.9 mm	0.377	1.086(0.905-1.303)	0.186	1.131(0.942-1.359)
7-9.9 mm	0.044	1.263(1.006-1.586)	0.780	1.033(0.821-1.300)
≥10mm	0.193	1.215(0.906-1.603)	0.558	1.093(0.812-1.473)
Treatment (reference to surgical treatment)				
Endovascular treatment	0.010	0.768(0.628-0.939)	0.044	0.810(0.661-0.994)
Conservative treatment	< 0.001	3.124(2.593-3.764)	< 0.001	2.589(2.131-3.146)
Admission delay, h	0.196	1.001(1.000-1.001)	0.218	1.001(1.000-1.001)


183 ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCircA,

It is made available under a CC-BY-NC 4.0 International license .

#### 184 posterior circulatory artery

### 185 Assessment of functional outcomes

Information on outcomes was available for 1,589 patients at discharge and for 1,399 patients after follow-up. Among them, 36.8% (515/1399) had favourable outcomes (mRS 0-2), and 10.1% (140/1399) were dependent (mRS 3-5) (Table S2). The distribution of mRS scores is shown in Figure 2. Among the 655 patients who were alive, 78.6% (515) had favourable outcomes, and 21.3% (140) were dependent. Binary logistic regression analysis of the mRS score at the time of follow-up (Table S3, Figure S3) revealed that WFNS grade V (OR [95% CI]: 3.593 [2.354–5.484], p<0.001) and aneurysms in the middle cerebral artery (OR [95% CI]: 1.815 [1.053–3.127], P=0.032) were



193 significantly associated with a greater risk of dependency.

194 Figure.2 Distribution of modified Rankin Scale (mRS) scores at discharge and at the time of

195 follow-up.

### 196 Subgroup analysis

- 197 Figure 3 and Table S4 present subgroup analyses of the associations between the three types of
- 198 treatment modalities and the risk of death. Compared with surgical treatment, conservative treatment
- 199 was associated with a greater risk of death in all subgroups (P<0.05). Compared with surgical

It is made available under a CC-BY-NC 4.0 International license .

- 200 treatment, endovascular treatment was associated with significantly better outcomes in patients under
- 201 65 years of age and those who were male, nonhypertensive, without a previous history of stroke,
- 202 without the coexistence of ICH/IVH, and with medium-sized aneurysms of 4–6.9 mm. Notably, the
- 203 WFNS grade may not influence the choice between surgical and endovascular treatment (p>0.05).
- 204 Interaction analysis indicated that conservative treatment may be safer for patients over 65 years old
- 205 or males than for those under 65 years old or females.

#### It is made available under a CC-BY-NC 4.0 International license .

Subgroup	Hazard Ratio(HR)	HR(95%CIs)	P.Value	P for interac
urgical Treatment(Reference)				
All patients				
Endovascular treatment Conservative treatment		0.768(0.628-0.939)	0.01* <0.001*	
		3.124(2.593-3.764)	NU.001	
Age <65				
Endovascular treatment	Here in the second seco	0.625(0.458-0.852)	0.003*	0.278
Conservative treatment		4.057(3.044-5.406)	<0.001*	< 0.001*
≥65				
Endovascular treatment	He H	0.782(0.598-1.024)	0.073	0.278
Conservative treatment	· ⊨●	2.144(1.670-2.752)	< 0.001*	<0.001*
Sex		× ,		
Male				
Endovascular treatment	Here and the second sec	0.652(0.471-0.905)	0.010*	0.175
Conservative treatment		2.424(1.794-3.275)	<0.001*	0.026*
Female				
Endovascular treatment	Her	0.868(0.672-1.123)	0.282	0.175
Conservative treatment	F <b>−●</b> −−−1	3.686(2.897-4.689)	<0.001*	0.026*
Hypertension				
No				
Endovascular treatment	H I I I I I I I I I I I I I I I I I I I	0.626(0.429-0.911)	0.014*	0.187
Conservative treatment		3.525(2.505-4.960)	<0.001*	0.413
Yes				
Endovascular treatment	He H	0.841(0.663-1.066)	0.153	0.187
Conservative treatment	. <b>⊢</b>	2.932(2.347-3.663)	<0.001*	0.413
Previous history of stroke				
No				
Endovascular treatment		0.764(0.613-0.953)	0.017*	0.728
Conservative treatment		3.280(2.666-4.036)	< 0.001	0.092
Yes				
Endovascular treatment		0.836(0.517-1.350)	0.464	0.728
Conservative treatment		2.308(1.508-3.534)	<0.001	0.092
Presence of ICH/IVH				
Yes	Hen!	0.658(0.482.0.807)	0.008*	0.006
Endovascular treatment Conservative treatment		0.658(0.483-0.897)	0.008*	0.096
Conservative treatment No		2.865(2.200-3.708)	<0.001	0.122
Endovascular treatment	He H	0.940(0.711-1.243)	0.663	0.096
Conservative treatment		3.615(2.751-4.751)	< 0.001	0.122
Size of the largest aneurysm	• •	5.015(2.751-4.751)	N0.001	0.122
<4.0 mm	He H	0.877(0.585-1.315)	0.526	
Endovascular treatment		3.481(2.409-5.030)	<0.001	Ref.
Conservative treatment		5.101(2.105 5.050)	-0.001	iter.
4.0-6.9 mm				
Endovascular treatment	le l	0.641(0.485-0.846)	0.002*	0.217
Conservative treatment		2.736(2.088-3.584)	<0.001	0.113
7-9.9 mm				
Endovascular treatment	<b>⊨</b> ∳4	0.972(0.569-1.662)	0.918	0.744
Conservative treatment		3.339(2.057-5.418)	< 0.001	0.714
≥10mm				
Endovascular treatment	<b>⊢∣e</b> €	1.120(0.559-2.245)	0.749	0.654
Conservative treatment	· · · · · · · · · · · · · · · · · · ·	5.557(2.843-10.859)	< 0.001	0.595
WFNS scale				
IV				
Endovascular treatment	He l	0.817(0.622-1.074)	0.147	0.665
Conservative treatment		3.468(2.635-4.566)	< 0.001	0.167
V				
Endovascular treatment	He H	0.895(0.660-1.214)	0.477	0.665
Conservative treatment		2.689(2.074-3.486)	< 0.001	0.167

206 Figure. 3 Subgroup analyses for the association between the treatment modality and death (surgical

207 treatment is the reference for analysis)

## 208 **DISCUSSION**

It is made available under a CC-BY-NC 4.0 International license .

To our knowledge, the current analysis represents the largest prospective, multicentre registry of

210	consecutive patients presenting with poor-grade aSAH. A total of 61.5% of the patients either died or
211	became dependent on survival. Our results indicate that the long-term mortality rate for poor-grade
212	aSAH in the Chinese population is 51%, and even among those who survived, 21.8% of the patients
213	were left with dependency status. Additionally, we estimated the risk factors contributing to death and
214	dependency. Our findings have important implications for evaluating the prognosis and management
215	of poor-grade aSAH.
216	In this study, we observed that the long-term all-cause mortality rate for severe aSAH patients
217	was 51.1%, with all-cause mortality rates at 3 months, 1 year, and 3 years being 40.9%, 43.5%, and
218	48.9%, respectively. de Oliveira Manoel retrospectively analysed 23 cohorts of unselected poor-grade
219	SAH patients treated from 1977 to 2014 in 10 countries and reported that the mortality rate was
220	approximately 60% <sup>17</sup> . This study reflects the mortality rate of poor-grade aSAH prior to 2014, which
221	was higher than the mortality rate in our study, with patients admitted between 2017 and 2020.
222	Furthermore, we performed a review of population-based case fatality after poor-grade aSAH to assess
223	whether case fatality had changed. After excluding studies with evident selection bias and those with
224	follow-up times of less than three months, a weighted linear regression analysis of the 19 studies
225	(including the present study) evaluating mortality revealed that the case fatality rate decreased by $0.6\%$
226	per year (95% CI $0.14$ to $0.97$ ), which, according to the model, corresponded to a 23% (6 to 40)
227	decrease in case fatality over the 30 years studied (Table S5). This trend is consistent with the
228	declining overall mortality rates of subarachnoid haemorrhage in recent years <sup>2, 3</sup> . Therefore, not only
229	the overall mortality rate but also the mortality rate of poor-grade aSAH is believed to decrease over $17$

It is made available under a CC-BY-NC 4.0 International license .

230	time; this is potentially due to early treatment (resulting from improved logistics and national health
231	system coverage), recent improvements in neurocritical care, the widespread use of cerebrospinal fluid
232	(CSF) drainage to buffer the massive increase in intracranial pressure (ICP) during rebleeding <sup>18</sup> , the
233	application of continuous electroencephalography, invasive brain multimodality monitoring, and the
234	use of nimodipine in the treatment of cerebral vasospasm <sup>5, 12, 19</sup> . Furthermore, advancements in
235	aneurysm repair techniques, including the maturation of surgical treatment and the widespread use of
236	endovascular treatment, have also led to some improvement in the mortality rate after poor-grade
237	aSAH. Although the mortality rate has declined in recent years, it was relatively higher in the present
238	study than in other countries in recent years, which may be related to a greater proportion of patients
239	being treated conservatively. This phenomenon may reflect the particularity of China's medical
240	environment, including special medical policies and conservative treatment choices under family
241	interventions <sup>20</sup> .
242	Survival analysis revealed that age $\geq$ 65 years, previous history of stroke, WFNS grade V, and
243	conservative treatment were risk factors for poor-grade aSAH. Age≥65 years, WFNS grade V,

conservative treatment were risk factors for poor-grade aSAH. Age≥65 years, WFNS grade V,
previous history of stroke, and conservative treatment as risk factors for poor-grade aSAH have been
repeatedly mentioned in previous studies<sup>21-23</sup>. We found that endovascular treatment is a protective
factor compared with surgical treatment, which is consistent with recent research findings<sup>22</sup>.
Interestingly, female sex is a protective factor against poor-grade aSAH, possibly because of regional
and hormonal factors<sup>15</sup>.

249 Through subgroup analysis of treatment methods, similar to previous studies, conservative 250 treatment had a worse prognosis in all subgroups compared with surgical or endovascular treatment.

It is made available under a CC-BY-NC 4.0 International license .

251 In addition, in the subgroup analysis for treatment, we discovered that endovascular treatment is 252 superior to surgical treatment in the subgroup of patients who are under 65 years old, male, 253 nonhypertensive, without a history of stroke, without coexisting ICH/IVH, and with aneurysm 254 diameters between 4–6.9 mm. Overall, endovascular treatment is better than surgical treatment and is 255 now widely used in clinical practice with good outcomes. Interaction tests revealed that the 256 disadvantage of conservative treatment is more pronounced in the younger group (aged <65) than in 257 the older group (aged  $\geq 65$ ), even though conservative treatment is often more severe conditions. The 258 results of this study suggest that providing the most aggressive treatment may be an effective way to 259 reduce mortality. Interestingly, although being female is a protective factor in this study, interaction 260 tests revealed that untreated female patients have a greater risk than male patients, which may imply 261 that a natural course is still a risk factor for poor prognosis in poor-grade aSAH patients. This 262 observation suggested that as much active treatment as possible should be provided to female patients. 263 During follow-up, 21.3% of the surviving patients were dependent on survival (mRS: 3-5) 264 (140/655). The proportion of patients with favourable outcomes (mRS: 0-2) among all the patients 265 was 36.8% (515/1,399), which was not significantly different from the approximately 39.7% reported 266 at discharge (597/1,589). Wang et al.<sup>22</sup> reported that the overall proportion of patients with favourable outcomes at 6 months was approximately 36.5%. Zhao et al.<sup>24</sup>, Robert M. Starke et al.<sup>25</sup>, and J Mocco 267 et al.<sup>26</sup> reported that the proportion of patients with favourable outcomes (mRS 0-2) at 12 months 268 269 among total poor-grade aSAH patients ranged from 33% to 42%, which is similar to our results. 270 Binary logistic regression analysis revealed that WFNS grade V is a significant predictor of dependency in patients with poor-grade aSAH, which is consistent with previous research<sup>17</sup>. Notably, 271

It is made available under a CC-BY-NC 4.0 International license .

272	middle cerebral artery aneurysm is an important risk factor for dependency in living patients, possibly
273	because when middle cerebral artery aneurysms rupture, the haematoma near the basal ganglia causes
274	destruction. In addition, cerebral vasospasm after haemorrhage can lead to ischaemia in the basal
275	ganglia area, thus affecting the motor system and causing patients to have dependency status.
276	Although this study revealed that different aneurysm treatment modalities could affect the long-term
277	mortality of patients, they are not risk factors for dependency. This phenomenon is consistent with the
278	conclusion of our research group that the dependency of 2-year survivors of aSAH among elderly
279	patients is not affected by the treatment modality <sup>27</sup> .
280	This study has several limitations. First, the results of this study are subject to the well-known
281	methodological limitations of retrospectively analysed cohorts, although we collected follow-up data
282	prospectively. Second, this study analysed multicentre data, and differences in treatment strategies
283	between centres may have introduced biases. However, all the centres were eligible cerebrovascular
284	centres in China, and operators in both groups were well trained. Third, there were missing data in this
285	study, and the database did not include complete imaging data. Finally, this study was limited to the
286	Chinese population, and ethnicity differences should be considered.

# 287 CONCLUSION

Our study revealed that among patients with poor-grade aSAH, 61.5% either died or became dependent. Although there has been a downward trend in recent years, the long-term mortality rate for poor-grade aSAH has reached 51%, and even among those who survived, 21.3% were dependent. The mortality rate significantly increased for patients who were WFNS Grade V, were older, had a previous history of stroke, and who received conservative treatment. Compared with surgical

It is made available under a CC-BY-NC 4.0 International license .

293	treatment, endovascular treatment is often more effective in reducing the mortality rate of poor-grade
294	aSAH patients. WFNS grade V and middle cerebral artery aneurysms are independent risk factors for
295	dependency. This study elucidates the long-term survival and dependency among poor-grade aSAH
296	patients, contributing clinical evidence to inform prognostic evaluations and treatment strategies.
297	Affiliations
298	Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300070, China.
299	Department of Neurosurgery, The Second Affiliated Hospital of Anhui Medical University, Hefei,
300	230601, China.
301	Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine,
302	Jinhua, 321000, Zhejiang, China.
303	Department of Emergency Surgery, The First Affiliated Hospital of Bengbu Medical University,
304	Bengbu, 233030, Anhui, China.
305	Department of Neurosurgery, Liaocheng People's hospital, Liaocheng, 252000, Shandong, China.
306	Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, 063000, Hebei, China.
307	Acknowledgments
308	We would like to express our sincere gratitude to all of the patients and their relatives as well as to the
309	professors from the Chinese Multicentre Aneurysm Database (CMAD) group.
310	Sources of Funding
311	This study was supported by the Natural Science Foundation of Tianjin, China (Grant No.
312	20JCZDJC00300), Tianjin Medical University Clinical Research Program (Grant No. 2018kylc008),
313	the Tianjin Medical University General Hospital Clinical Research Program (Grant No. 21

It is made available under a CC-BY-NC 4.0 International license .

- 314 22ZYYLCCG07), and The Second Affiliated Hospital of Anhui Medical University Science and
- 315 Technology Emerging Talents Enhancement Program (Grant No. 2024PY07). The authors have
- 316 disclosed that they do not have any potential conflicts of interest.
- 317 **Disclosures**
- 318 None.
- 319 Supplemental Material
- 320 Table S1-S5
- 321 Figure S1-S3

It is made available under a CC-BY-NC 4.0 International license .

## 322 **REFERENCES**

- 323 1. Rinkel GJE, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid
- 324 haemorrhage. *The Lancet Neurology*. 2011;10:349-356
- 325 2. Lv B, Lan J-X, Si Y-F, Ren Y-F, Li M-Y, Guo F-F, et al. Epidemiological trends of
- 326 subarachnoid hemorrhage at global, regional, and national level: A trend analysis study
- 327 from 1990 to 2021. *Military Medical Research*. 2024;11
- 328 3. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case
- 329 fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and
- 330 region: A meta-analysis. *Lancet Neurol.* 2009;8:635-642
- 4. Thilak S, Brown P, Whitehouse T, Gautam N, Lawrence E, Ahmed Z, et al. Diagnosis and
- 332 management of subarachnoid haemorrhage. *Nature communications*. 2024;15:1850
- 333 5. de Oliveira Manoel AL, Goffi A, Marotta TR, Schweizer TA, Abrahamson S, Macdonald RL.
- 334 The critical care management of poor-grade subarachnoid haemorrhage. Critical care
- 335 *(London, England)*. 2016;20:21
- Al-Mufti F, Mayer SA, Kaur G, Bassily D, Li B, Holstein ML, et al. Neurocritical care
   management of poor-grade subarachnoid hemorrhage: Unjustified nihilism to reasonable
- 338 optimism. *The neuroradiology journal*. 2021;34:542-551
- 339 7. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European stroke
- 340 organization guidelines for the management of intracranial aneurysms and subarachnoid
- 341 haemorrhage. *Cerebrovascular diseases (Basel, Switzerland)*. 2013;35:93-112

It is made available under a CC-BY-NC 4.0 International license .

- 342 8. Schuss P, Hadjiathanasiou A, Borger V, Wispel C, Vatter H, Güresir E. Poor-grade
- 343 aneurysmal subarachnoid hemorrhage: Factors influencing functional outcome--a
- 344 single-center series. *World Neurosurg.* 2016;85:125-129
- 345 9. Shen J, Yu J, Huang S, Mungur R, Huang K, Pan X, et al. Scoring model to predict
- functional outcome in poor-grade aneurysmal subarachnoid hemorrhage. *Frontiers in neurology*. 2021;12:601996
- 348 10. Stauning AT, Eriksson F, Benndorf G, Holst AV, Hauerberg J, Stavngaard T, et al.
- 349 Mortality among patients treated for aneurysmal subarachnoid hemorrhage in eastern
- 350 denmark 2017-2019. *Acta Neurochir (Wien)*. 2022;164:2419-2430
- 11. Schatlo B, Fung C, Stienen MN, Fathi AR, Fandino J, Smoll NR, et al. Incidence and
- 352 outcome of aneurysmal subarachnoid hemorrhage: The swiss study on subarachnoid

353 hemorrhage (swiss sos). *Stroke*. 2021;52:344-347

- 12. Lantigua H, Ortega-Gutierrez S, Schmidt JM, Lee K, Badjatia N, Agarwal S, et al.
- 355 Subarachnoid hemorrhage: Who dies, and why? *Critical care (London, England)*. 356 2015;19:309
- Hoogmoed J, Coert BA, van den Berg R, Roos Y, Horn J, Vandertop WP, et al. Early
   treatment decisions in poor-grade patients with subarachnoid hemorrhage. *World Neurosurg.* 2018;119:e568-e573
- Liu J, Xiong Y, Zhong M, Yang Y, Guo X, Tan X, et al. Predicting long-term outcomes after
   poor-grade aneurysmal subarachnoid hemorrhage using decision tree modeling.

It is made available under a CC-BY-NC 4.0 International license .

362 <i>Neurosurgery</i> . 2020;87:52	23-529
--------------------------------------	--------

- 363 15. Wilby MJ, Sharp M, Whitfield PC, Hutchinson PJ, Menon DK, Kirkpatrick PJ.
- 364 Cost-effective outcome for treating poor-grade subarachnoid hemorrhage. *Stroke*.
- 365 2003;34:2508-2511
- 16. Komotar RJ, Schmidt JM, Starke RM, Claassen J, Wartenberg KE, Lee K, et al.
- 367 Resuscitation and critical care of poor-grade subarachnoid hemorrhage. *Neurosurgery*.
- 368 2009;64:397-410; discussion 410-391
- 369 17. de Oliveira Manoel AL, Mansur A, Silva GS, Germans MR, Jaja BN, Kouzmina E, et al.
- 370 Functional outcome after poor-grade subarachnoid hemorrhage: A single-center study

and systematic literature review. *Neurocritical care*. 2016;25:338-350

37218.Bailes JE, Spetzler RF, Hadley MN, Baldwin HZ. Management morbidity and mortality of

373 poor-grade aneurysm patients. *Journal of neurosurgery*. 1990;72:559-566

- 19. Panni P, Riccio L, Cao R, Pedicelli A, Marchese E, Caricato A, et al. Clinical impact and
- 375 predictors of aneurysmal rebleeding in poor-grade subarachnoid hemorrhage: Results

376 from the national pogash registry. *Neurosurgery*. 2023;93:636-645


- 377 20. Yang Y, Wang B, Ge X, Lu W, Peng C, Zhao Y, et al. Natural course of ruptured but
  378 untreated intracranial aneurysms: A multicenter 2-year follow-up study. *Stroke*.
- 379 2023;54:2087-2095
- de Winkel J, Cras TY, Dammers R, van Doormaal PJ, van der Jagt M, Dippel DWJ, et al.
   Early predictors of functional outcome in poor-grade aneurysmal subarachnoid

It is made available under a CC-BY-NC 4.0 International license .

382		hemorrhage: A systematic review and meta-analysis. <i>BMC neurology</i> . 2022;22:239
383	22.	Wang X, Han C, Xing D, Wang C, Ding X. Early management of poor-grade aneurysmal
384		subarachnoid hemorrhage: A prognostic analysis of 104 patients. Clinical neurology and
385		neurosurgery. 2019;179:4-8
386	23.	Chen C, Guo X, Chen Y, Zheng K, Zhou J, Wang H, et al. Predictors of poor-grade
387		aneurysmal subarachnoid hemorrhage caused by anterior communicating artery
388		aneurysm. World Neurosurg. 2021;148:e340-e345
389	24.	Zhao B, Fan Y, Xiong Y, Yin R, Zheng K, Li Z, et al. Aneurysm rebleeding after poor-grade
390		aneurysmal subarachnoid hemorrhage: Predictors and impact on clinical outcomes.
391		Journal of the neurological sciences. 2016;371:62-66
392	25.	Starke RM, Komotar RJ, Kim GH, Kellner CP, Otten ML, Hahn DK, et al. Evaluation of a
393		revised glasgow coma score scale in predicting long-term outcome of poor grade
394		aneurysmal subarachnoid hemorrhage patients. Journal of clinical neuroscience : official
395		journal of the Neurosurgical Society of Australasia. 2009;16:894-899
396	26.	Mocco J, Ransom ER, Komotar RJ, Sergot PB, Ostapkovich N, Schmidt JM, et al.
397		Long-term domain-specific improvement following poor grade aneurysmal subarachnoid
398		hemorrhage. Journal of neurology. 2006;253:1278-1284
399	27.	Wang BY, Peng C, Jiang HS, Yang ZH, Zhao Y, Song YF, et al. The survival and outcome
400		of older patients with primary aneurysmal subarachnoid haemorrhage: A 2-year follow-up,
401		multi-centre, observational study. Age and ageing. 2023;52

402

It is made available under a CC-BY-NC 4.0 International license .



Treatment 🕂 Cliping 🕂 Coiling 🚽 Conservative

Previous history of stroke 🗕 No 🕂 Yes

It is made available under a CC-BY-NC 4.0 International license .

23.3%

10%

7.3%

0%

19.1%

20%

Follow-up

Discharge

11.8%

8.3%

30%

3.7%

3.4% 3.2% 2.5% 4.7%

40%

12.9%

50%

mRS scale 0 1 2 3 4 5 6

60%

51.1%

80%

10.3%

100%

90%

38.4%

70%

### It is made available under a CC-BY-NC 4.0 International license .

Subgroup	Hazard Ratio(HR)	HR(95%CIs)	P.Value	P for interaction
Surgical Treatment(Reference)				
All patients				
Endovascular treatment		0.768(0.628-0.939)	0.01*	
Conservative treatment		3.124(2.593-3.764)	< 0.001*	
Age				
<65				
Endovascular treatment	Here and the second sec	0.625(0.458-0.852)	0.003*	0.278
Conservative treatment		4.057(3.044-5.406)	<0.001*	<0.001*
≥65				
Endovascular treatment		0.782(0.598-1.024)	0.073	0.278
Conservative treatment Sex		2.144(1.670-2.752)	<0.001*	<0.001*
Male				
Endovascular treatment		0.652(0.471-0.905)	0.010*	0.175
Conservative treatment		2.424(1.794-3.275)	<0.001*	0.026*
Female				
Endovascular treatment	H	0.868(0.672-1.123)	0.282	0.175
Conservative treatment		3.686(2.897-4.689)	<0.001*	0.026*
Hypertension				
No		0.0000.000.0000	0.014*	0.107
Endovascular treatment Conservative treatment		0.626(0.429-0.911) 3.525(2.505-4.960)	0.014* <0.001*	0.187 0.413
Conservative treatment Yes		5.525(2.505-4.900)	NU.UUI '	0.413
Endovascular treatment	<b>⊷</b> 4	0.841(0.663-1.066)	0.153	0.187
Conservative treatment	│ <b>⊨_⊕</b> ↓	2.932(2.347-3.663)	<0.001*	0.413
Previous history of stroke				
No				
Endovascular treatment		0.764(0.613-0.953)	0.017*	0.728
Conservative treatment		3.280(2.666-4.036)	<0.001	0.092
Yes Endovascular treatment		0.826(0.517.1.250)	0.464	0.728
Conservative treatment		0.836(0.517-1.350) 2.308(1.508-3.534)	< 0.404	0.092
Presence of ICH/IVH		2.500(1.500-5.554)	0.001	0.072
Yes				
Endovascular treatment	Here and the second sec	0.658(0.483-0.897)	0.008*	0.096
Conservative treatment	<b>⊢</b> ●—1	2.865(2.200-3.708)	<0.001	0.122
No				
Endovascular treatment		0.940(0.711-1.243)	0.663	0.096
Conservative treatment Size of the largest aneurysm		3.615(2.751-4.751)	<0.001	0.122
<4.0 mm	He H	0.877(0.585-1.315)	0.526	
Endovascular treatment		3.481(2.409-5.030)	<0.001	Ref.
Conservative treatment				
4.0-6.9 mm				
Endovascular treatment		0.641(0.485-0.846)	0.002*	0.217
Conservative treatment		2.736(2.088-3.584)	<0.001	0.113
7-9.9 mm		0.072/0.560.1.662)	0.018	0.744
Endovascular treatment Conservative treatment		0.972(0.569-1.662) 3.339(2.057-5.418)	0.918 <0.001	0.744 0.714
≥10mm		5.557(2.057-5.410)	<0.001	0.714
Endovascular treatment	<b>⊨</b>	1.120(0.559-2.245)	0.749	0.654
Conservative treatment		5.557(2.843-10.859)	< 0.001	0.595
WFNS scale				
IV				
Endovascular treatment		0.817(0.622-1.074)	0.147	0.665
Conservative treatment V		3.468(2.635-4.566)	<0.001	0.167
v Endovascular treatment	He-H	0.895(0.660-1.214)	0.477	0.665
Conservative treatment		2.689(2.074-3.486)	<0.001	0.167